Home  |  About SITC  |  Contact Us


SITC & Cancer Immunotherapy: When Vision Becomes Reality

SITC members lead the cancer immunotherapy revolution impacting the care of patients with cancer.

Sunday, November 8

Press Release

SITC among First to Address Value Proposition of Cancer Immunotherapy

Saturday, November 7

SITC 2015 Awardees

Congratulations to all SITC 2015 awardees! This year, SITC presented more than 60 awards to young investigators, members and luminaries in the field. Download the 30th Anniversary Award Ceremony booklet here.

Friday, November 6

Press Release

Preliminary Results from Phase I/II Study of Epacadostat in Combination with Pembrolizumab Demonstrates 53% Overall Response Rate across a Number of Cancer Types

Dr. Howard L. Kaufman on Impact of T-VEC FDA Approval via OncLive

Howard L. Kaufman, MD, FACS, Chief Surgical Officer, Associate Director for Clinical Science, Surgical Oncologist, Rutgers Cancer Institute, Society for Immunotherapy of Cancer (SITC) President, discusses the impact of the recent FDA approval of talimogene laherparepvec (T-VEC) for the treatment of melanoma lesions in the skin and lymph nodes. Read more.

Thursday, November 5

Dr. Stephen Grupp on Engineered Cell Therapy for the Treatment of Pediatric ALL via OncLive

Stephen Grupp, MD, PhD, director of translational research for the center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP) and medical director of the Stem Cell Laboratory at CHOP, discusses the use of engineered cell therapy for the treatment of Acute Lymphoblastic Leukemia (ALL) in children. Read more.

Wednesday, November 4

Journal for ImmunoTherapy of Cancer 30th Anniversary Annual Meeting Abstract Supplement

Access all accepted SITC 2015 abstracts here.

Connect with SITC!

SITC: Join Today